MCID: CRN017
MIFTS: 47

Coronary Thrombosis

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Coronary Thrombosis

MalaCards integrated aliases for Coronary Thrombosis:

Name: Coronary Thrombosis 12 54 43 15 17 71
Coronary Artery Thrombosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11847
MeSH 43 D003328
SNOMED-CT 67 66514008
ICD10 32 I21 I22
UMLS 71 C0010072

Summaries for Coronary Thrombosis

MalaCards based summary : Coronary Thrombosis, also known as coronary artery thrombosis, is related to heparin-induced thrombocytopenia and endocarditis. An important gene associated with Coronary Thrombosis is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Degradation of the extracellular matrix. The drugs Clopidogrel and Ticagrelor have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and neutrophil, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Coronary thrombosis is the formation of a blood clot inside a blood vessel of the heart. This blood clot... more...

Related Diseases for Coronary Thrombosis

Diseases related to Coronary Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 heparin-induced thrombocytopenia 30.5 SERPINC1 F3
2 endocarditis 30.5 SERPINE1 SERPINC1 PLAT
3 aspirin resistance 30.3 PTGS2 ITGB3
4 thrombophilia due to thrombin defect 30.2 SERPINE1 SERPINC1 PLAT F3
5 inferior myocardial infarction 30.1 PLG PLAT
6 catastrophic antiphospholipid syndrome 30.1 SERPINE1 F3
7 protein s deficiency 30.0 SERPINE1 SERPINC1 F3
8 homocysteinemia 29.9 VWF SERPINE1 SERPINC1
9 acute anterolateral myocardial infarction 29.7 PLG ITGA2B
10 antithrombin iii deficiency 29.7 SERPINC1 PLG FGA
11 splenic infarction 29.7 SERPINC1 F3
12 cardiac tamponade 29.6 PLAT F7 F3
13 atrial heart septal defect 29.6 SERPINC1 PLG PLAT F3
14 factor viii deficiency 29.6 VWF F7 F3
15 hemophilia a 29.6 VWF F7 F3
16 pulmonary embolism 29.6 VWF SERPINE1 SERPINC1 PLAT GP6 F3
17 atherosclerosis susceptibility 29.4 VWF SERPINE1 SELP PLAT F3
18 platelet aggregation, spontaneous 29.3 VWF SERPINC1 SELP PLAT
19 thrombocytosis 29.2 VWF SERPINC1 SELP FGA F3
20 hemophilia b 29.1 VWF SERPINC1 FGA F7 F3
21 intracranial embolism 29.0 WDTC1 SERPINC1 PLG PLAT F3
22 antiphospholipid syndrome 28.9 VWF SERPINE1 SERPINC1 SELP PLAT F3
23 migraine with or without aura 1 28.8 WDTC1 SLC6A4 PTGS2 PLG
24 thrombocytopenic purpura, autoimmune 28.7 SELP ITGB3 ITGA2B GP6 GP1BA
25 coronary artery anomaly 28.7 SERPINE1 SERPINC1 SELP PLG PLAT F3
26 arteriosclerosis 28.5 SERPINE1 SERPINC1 SELP ITGB3 ITGA2B F3
27 coronary heart disease 1 28.5 VWF SERPINE1 SELP PLAT F7
28 thrombotic thrombocytopenic purpura 28.4 VWF SERPINC1 SELP PLAT ITGB3 F3
29 arteries, anomalies of 28.2 VWF SERPINE1 SELP PLG PLAT P2RY12
30 purpura 28.2 VWF SERPINC1 SELP ITGB3 ITGA2B GP1BA
31 von willebrand's disease 28.1 VWF SELP PLAT P2RY12 ITGB3 GP6
32 essential thrombocythemia 27.9 VWF SERPINE1 SERPINC1 SELP ITGB3 ITGA2B
33 disseminated intravascular coagulation 27.7 VWF SERPINE1 SERPINC1 PLG PLAT FGA
34 intermediate coronary syndrome 27.6 WDTC1 VWF SERPINC1 SELP PLG PLAT
35 diabetes mellitus 27.6 VWF SERPINE1 SERPINC1 SELP PTGS2 PLAT
36 acute myocardial infarction 27.4 VWF SERPINE1 SERPINC1 SELP PLG PLAT
37 thrombosis 27.3 VWF SERPINE1 SERPINC1 SELP PLG PLAT
38 heart disease 27.3 VWF SLC6A4 SERPINE1 SERPINC1 SELP PLAT
39 thrombophlebitis 27.1 VWF SERPINE1 SERPINC1 SELP PLG PLAT
40 thrombophilia 27.0 VWF SERPINE1 SERPINC1 SELP PLG PLAT
41 thrombocytopenia 26.9 VWF SERPINE1 SERPINC1 SELP POU2F3 PLAT
42 intracranial thrombosis 26.5 WDTC1 VWF SERPINC1 SELP PLG PLAT
43 carotid artery thrombosis 26.4 WDTC1 VWF SERPINE1 SERPINC1 SELP PLG
44 vascular disease 26.0 VWF SLC6A4 SERPINE1 SERPINC1 SELP PTGS2
45 myocardial infarction 25.9 VWF SLC6A4 SERPINE1 SERPINC1 SELP PTGS2
46 hypertension, essential 24.9 WDTC1 VWF SLC6A4 SERPINE1 SERPINC1 SELP
47 arterial calcification of infancy 11.3
48 sudden sensorineural hearing loss 10.5 SERPINC1 ITGB3
49 arteritic anterior ischemic optic neuropathy 10.4 ITGB3 GP1BA
50 cardiac tuberculosis 10.4 SERPINE1 SERPINC1

Graphical network of the top 20 diseases related to Coronary Thrombosis:



Diseases related to Coronary Thrombosis

Symptoms & Phenotypes for Coronary Thrombosis

MGI Mouse Phenotypes related to Coronary Thrombosis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 F3 F7 FGA ITGA2B ITGB3 PLAT
2 homeostasis/metabolism MP:0005376 10.39 F3 F7 FGA GP1BA GP6 ITGA2B
3 hematopoietic system MP:0005397 10.35 F3 FGA GP1BA GP6 ITGA2B ITGB3
4 cellular MP:0005384 10.25 F3 GP1BA ITGA2B ITGB3 PLAT PLG
5 immune system MP:0005387 10.25 F3 FGA GP6 ITGA2B ITGB3 PLAT
6 mortality/aging MP:0010768 10.2 F3 F7 FGA GP6 ITGB3 PLAT
7 digestive/alimentary MP:0005381 10.15 FGA ITGA2B ITGB3 PLAT PLG PTGS2
8 integument MP:0010771 10.14 F3 FGA GP6 ITGB3 PLAT PLG
9 nervous system MP:0003631 10 F3 FGA ITGB3 PLAT PLG PTGS2
10 liver/biliary system MP:0005370 9.91 FGA ITGB3 PLG PTGS2 SELP SERPINC1
11 reproductive system MP:0005389 9.85 FGA GP6 ITGA2B ITGB3 PLAT PLG
12 respiratory system MP:0005388 9.5 F3 ITGB3 PLAT PLG PTGS2 SELP
13 vision/eye MP:0005391 9.32 F3 FGA GP6 ITGB3 PLAT PLG

Drugs & Therapeutics for Coronary Thrombosis

Drugs for Coronary Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Ticagrelor Approved Phase 4 274693-27-5 9871419
3
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
4
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Tirofiban Approved Phase 4 144494-65-5 60947
9 Neurotransmitter Agents Phase 4
10 Purinergic P2Y Receptor Antagonists Phase 4
11 Respiratory System Agents Phase 4
12 Anti-Asthmatic Agents Phase 4
13 Protective Agents Phase 4
14 Neuroprotective Agents Phase 4
15 Autonomic Agents Phase 4
16 Bronchodilator Agents Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Phosphodiesterase 3 Inhibitors Phase 4
19 Immunosuppressive Agents Phase 4
20 Antibiotics, Antitubercular Phase 4
21 Immunologic Factors Phase 4
22 Antifungal Agents Phase 4
23 Hypolipidemic Agents Phase 4
24 Anticholesteremic Agents Phase 4
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
26 Antimetabolites Phase 4
27 Lipid Regulating Agents Phase 4
28
tannic acid Approved Phase 3 1401-55-4
29
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
30
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
31
Chromium Approved Phase 3 7440-47-3 27668
32
Streptokinase Approved, Investigational Phase 3 9002-01-1
33
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
34
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
35 Trace Elements Phase 3
36 Micronutrients Phase 3
37 Nutrients Phase 3
38 Vasodilator Agents Phase 3
39 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid Phase 3
40
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 23925 27284
41
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
42
Protein C Approved Phase 2
43 Nutmeg Approved Phase 2
44 Ferrosoferric Oxide Phase 2
45 Hematinics Phase 2
46 Pharmaceutical Solutions Phase 2
47 Parenteral Nutrition Solutions Phase 2
48 Anticoagulants Phase 2
49 Thromboplastin Phase 2
50 Mace Phase 2

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
2 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
3 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
4 Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification Completed NCT02225834 Phase 4 Atorvastatin
5 Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial Completed NCT02577965 Phase 4
6 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
7 Treatment by Anti GP IIb/IIIa in the Setting of a Strategy of Early Coronarography to Patients With an Acute Coronary Syndrome Without ST Elevation Terminated NCT00445263 Phase 4 TIROFIBAN
8 Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course Withdrawn NCT00713947 Phase 4 during one week for the active treatments;Pantoprazole;Placebo Formula 515
9 A Randomized Trial of Bare Metal Stent (Cronus®) - Cobalt Chromium Versus Stent Coating With Sirolimus (DES) Completed NCT01093391 Phase 3
10 Intravenous Streptokinase in Acute Myocardial Infarction Completed NCT00000507 Phase 3 streptokinase
11 Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries Completed NCT00000503 Phase 3 nitroglycerin;streptokinase
12 Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction Not yet recruiting NCT04043091 Phase 3
13 A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study). Suspended NCT00353067 Phase 3 veliflapon (DG-031)
14 A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Terminated NCT00557921 Phase 3 CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;Plavix (clopidogrel 75 mg) and aspirin
15 ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide Unknown status NCT01995799 Phase 2
16 A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome Completed NCT00619164 Phase 2 E5555;E5555;E5555;Placebo
17 A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment #3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin Completed NCT00116012 Phase 2 rNAPc2
18 Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study Completed NCT01274234 Phase 1, Phase 2
19 Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3 Unknown status NCT02591264
20 Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals Unknown status NCT00973375
21 Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy Unknown status NCT00327041
22 Study of ABSORB Stent in Acute Coronary Syndrome Unknown status NCT02071342
23 Does the Human Gut Microbiome Serve as a Novel Personalized Therapeutic Target for Coronary Atherosclerosis? Unknown status NCT03009565
24 Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease Unknown status NCT00407368
25 Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor in Patients Who Have Previously Undergone PCI Procedures and Insertion of Coronary Stents Completed NCT02297971
26 Xtract™ Aspiration Catheter Registry Study Completed NCT00349570
27 Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department Completed NCT00657436
28 A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic Completed NCT00714623
29 Thrombogenic Factors and Recurrent Coronary Events Completed NCT00005358
30 Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia Completed NCT00169871
31 Optical Frequency Domain Imaging-Quantified Intracoronary Thrombus Mass During Primary Percutaneous Coronary Intervention, Its Relationship With Antiplatelet Pretreatment Effect And Its Impact On Myocardial Reperfusion Completed NCT03342521
32 Optical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease: OCT and CMR Study (SOFT-MI) Completed NCT02783963
33 Single-centre, Prospective, Randomised, Placebo-controlled, Parallel-group Design to Determine the Cholesterol-lowering Efficacy of Lactobacillus Plantarum ECGC 13110402 in Normal to Mildly Hypercholesterolaemic Adults Completed NCT03263104
34 Thrombotic, Inflammatory & Gene Markers of CVD in Women Completed NCT00006539
35 Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry Completed NCT03180931
36 Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease. Completed NCT03034148
37 Etiology of Myocardial Injury Following Non-cardiac Surgery - a Prospective Clinical Trial Recruiting NCT03317561
38 Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions Recruiting NCT03223974
39 Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome Recruiting NCT02562690
40 Long Term Clinical Outcomes of Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions: a Single Center Registry Study Recruiting NCT04022200
41 Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Recruiting NCT04022668
42 EKG Criteria and Identification of Acute Coronary Occlusion Recruiting NCT03863327
43 Proteomic and Lipidomic Profiling of Coronary Thrombus in Acute Myocardial Infarction Recruiting NCT03731884
44 Predictive Value of HAS-BLED and CHA2DS2-Vasc Scores for Clinical Outcome After PCI Not yet recruiting NCT04047199
45 The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum ECGC 13110402 (LPLDL®) in Hypercholesterolemic Adults Not yet recruiting NCT03540108

Search NIH Clinical Center for Coronary Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Tenecteplase
Urokinase

Cochrane evidence based reviews: coronary thrombosis

Genetic Tests for Coronary Thrombosis

Anatomical Context for Coronary Thrombosis

MalaCards organs/tissues related to Coronary Thrombosis:

40
Heart, Endothelial, Neutrophil, Testes, Smooth Muscle, Kidney, Myeloid

Publications for Coronary Thrombosis

Articles related to Coronary Thrombosis:

(show top 50) (show all 2308)
# Title Authors PMID Year
1
[Annexin A5 inhibits homocysteine-induced tissue factor expression and activity in vascular smooth muscle cells]. 61 54
20137335 2009
2
Atherothrombosis: role of tissue factor; link between diabetes, obesity and inflammation. 54 61
17249334 2007
3
Rapid release of active tissue factor from human arterial smooth muscle cells under flow conditions. 54 61
16528008 2006
4
Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction. 61 54
16377278 2006
5
[Regulatory effect of IL-10 on expression of tissue factor induced by IL-6 in peripheral blood mononuclear cells]. 61 54
15972146 2005
6
Angiographic demonstration of coronary dethrombosis with eptifibatide. 54 61
15156011 2004
7
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 61 54
14963043 2004
8
How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. 61 54
12808446 2003
9
Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report. 61 54
12644882 2003
10
Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. 61 54
11028489 2000
11
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. 61 54
10928474 2000
12
Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Témoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. 61 54
10712418 2000
13
The PlA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection. 54 61
10589700 1999
14
Glycoprotein IIIa Pl(A) polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. 54 61
10521390 1999
15
Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. 54 61
10199872 1999
16
Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis. 54 61
9796837 1998
17
Coronary thrombosis associated with antithrombin-III deficiency. 61 54
9327319 1997
18
Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. 61 54
9012634 1997
19
Identification of active tissue factor in human coronary atheroma. 61 54
8822973 1996
20
Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. 61 54
8725732 1996
21
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. 61 54
8735626 1996
22
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. 54 61
7641354 1995
23
Novel antithrombotic approaches to coronary artery disease. 54 61
7863968 1995
24
Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. 54 61
8026028 1994
25
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. 54 61
1451271 1992
26
Reduced synthesis of tissue plasminogen activator by vascular endothelium during acute myocardial infarction. 61 54
1497553 1992
27
Role of heparin in coronary thrombolysis. 61 54
1555478 1992
28
Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. 61 54
1606285 1992
29
Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig. 61 54
1513078 1992
30
Lifetime cardiovascular management of patients with previous Kawasaki disease. 61
31843876 2019
31
Understanding Vulnerable Plaques: Current Status and Future Directions. 61
31760703 2019
32
Acute Bilateral Coronary Artery Thrombosis and Myocardial Infarction in a 25-Year-Old Man After Long-Term Oral Clozapine Treatment. 61
31834089 2019
33
Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction. 61
31280622 2019
34
PBMCs-Derived microRNA Signature as a Prethrombotic Status Discriminator in Stable Coronary Artery Disease. 61
31715633 2019
35
Adaptation to Extreme Environments in an Admixed Human Population from the Atacama Desert. 61
31384924 2019
36
In-situ Coronary Thrombosis in Antiphospholipid Syndrome: A Case Report. 61
31723491 2019
37
Incidence, characteristics and outcomes in very young patients with ST segment elevation myocardial infarction. 61
31524668 2019
38
Incomplete Kawasaki disease with development of fatal coronary artery thrombosis in a 13-year-old male. 61
31306942 2019
39
Therapeutic Ultrasound Increases Myocardial Blood Flow in Ischemic Myocardium and Cardiac Endothelial Cells: Results of In Vivo and In Vitro Experiments. 61
31272838 2019
40
High Levels of Circulating MicroRNA-3667-3p Are Associated with Coronary Plaque Erosion in Patients with ST-Segment Elevation Myocardial Infarction. 61
31484870 2019
41
Correlation between intracoronary thrombus components and coronary blood flow after percutaneous coronary intervention for acute myocardial infarction at different onset time. 61
31423433 2019
42
[Coronary involvement and nephrotic syndrome in systemic lupus: A case report]. 61
30981562 2019
43
Sudden unexpected death due to coronary thrombosis associated with isolated necrotizing vasculitis in the coronary arteries of a young adult. 61
30810977 2019
44
Clinical Significance of Platelet Volume and Other Platelet Parameters in Acute Myocardial Infarction and Stable Coronary Artery Disease. 61
30942294 2019
45
Isotretinoin-associated possible Kounis syndrome: A case report and a review of other cardiovascular side effects reported in the literature. 61
31219450 2019
46
Expression profile of integrin family genes in patients with myocardial infarction and in healthy subjects: an oligonucleotide microarray and QRT-PCR assessment. Preliminary results. 61
30784245 2019
47
Targeting thrombogenicity and inflammation in chronic HIV infection. 61
31206016 2019
48
Intracoronary recombinant tissue plasminogen activator in an infant with hypoplastic left heart syndrome and complete left main coronary artery thrombosis. 61
30702202 2019
49
Coronary Artery Thrombosis in a Neonate With Critical Aortic Stenosis. 61
31034441 2019
50
Pulmonary thromboembolism and coronary thrombosis after chemotherapy with cisplatin: simultaneous diagnosis with non-ECG gated computed tomography. 61
31210696 2019

Variations for Coronary Thrombosis

Expression for Coronary Thrombosis

Search GEO for disease gene expression data for Coronary Thrombosis.

Pathways for Coronary Thrombosis

Pathways related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 VWF SERPINE1 SERPINC1 SELP PLG PLAT
2
Show member pathways
12.64 SERPINE1 PLG ITGB3 ITGA2B FGA
3
Show member pathways
12.23 SERPINE1 PTGS2 PLG PLAT F7
4
Show member pathways
12.18 VWF ITGB3 ITGA2B FGA
5
Show member pathways
12.04 VWF ITGB3 ITGA2B GP6 GP1BA FGA
6
Show member pathways
11.97 VWF ITGB3 ITGA2B FGA
7 11.96 VWF P2RY12 ITGB3 ITGA2B GP6 GP1BA
8 11.92 VWF SERPINE1 SERPINC1 PLG PLAT FGA
9 11.91 SERPINE1 PLG ITGB3 F3
10 11.85 ITGB3 ITGA2B GP1BA
11
Show member pathways
11.79 VWF ITGB3 ITGA2B GP1BA FGA
12 11.77 ITGB3 ITGA2B GP1BA
13 11.76 VWF PTGS2 ITGB3 F3
14 11.53 SERPINE1 PLG PLAT
15
Show member pathways
11.52 VWF SERPINE1 SERPINC1 PLG PLAT GP6
16 11.49 SERPINE1 ITGB3 ITGA2B
17 11.44 VWF P2RY12 ITGB3 ITGA2B GP6 FGA
18 11.42 SELP PLG PLAT GP1BA
19 11.41 PLG PLAT FGA
20 10.77 VWF GP6 GP1BA
21 10.75 SERPINE1 PLG PLAT
22 10.59 VWF GP1BA

GO Terms for Coronary Thrombosis

Cellular components related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.25 SLC6A4 SERPINE1 SERPINC1 SELP POU2F3 PLG
2 extracellular region GO:0005576 10.13 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT
3 extracellular space GO:0005615 10.02 SERPINF1 SERPINE1 SERPINC1 SELP PLG PLAT
4 extracellular exosome GO:0070062 9.9 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT
5 endoplasmic reticulum lumen GO:0005788 9.81 SERPINC1 PTGS2 FGA F7
6 blood microparticle GO:0072562 9.76 SERPINC1 PLG ITGA2B FGA
7 cell surface GO:0009986 9.61 PLG PLAT P2RY12 ITGB3 ITGA2B GP6
8 platelet alpha granule lumen GO:0031093 9.56 VWF SERPINE1 PLG FGA
9 platelet alpha granule membrane GO:0031092 9.54 SELP ITGB3 ITGA2B
10 platelet alpha granule GO:0031091 9.49 VWF FGA
11 serine-type peptidase complex GO:1905286 9.43 F7 F3
12 collagen-containing extracellular matrix GO:0062023 9.28 VWF SERPINF1 SERPINE1 SERPINC1 PLG PLAT

Biological processes related to Coronary Thrombosis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 10.01 VWF SELP ITGB3 ITGA2B GP1BA
2 extracellular matrix organization GO:0030198 9.8 VWF SERPINE1 ITGB3 ITGA2B FGA
3 platelet activation GO:0030168 9.8 VWF P2RY12 ITGB3 GP6 GP1BA FGA
4 response to estradiol GO:0032355 9.77 SLC6A4 PTGS2 F7
5 platelet aggregation GO:0070527 9.77 P2RY12 ITGB3 ITGA2B GP1BA FGA
6 cell-matrix adhesion GO:0007160 9.76 ITGB3 ITGA2B FGA
7 circadian rhythm GO:0007623 9.74 SLC6A4 SERPINE1 F7
8 platelet degranulation GO:0002576 9.7 VWF SERPINE1 SELP PLG ITGB3 ITGA2B
9 fibrinolysis GO:0042730 9.65 SERPINE1 PLG PLAT GP1BA FGA
10 cellular response to ATP GO:0071318 9.62 PTGS2 P2RY12
11 cell-substrate adhesion GO:0031589 9.62 VWF ITGB3
12 blood coagulation, intrinsic pathway GO:0007597 9.61 VWF GP1BA
13 hemostasis GO:0007599 9.61 VWF SERPINC1 PLG P2RY12 GP6 GP1BA
14 positive regulation of blood coagulation GO:0030194 9.59 SERPINE1 F7
15 positive regulation of leukocyte migration GO:0002687 9.58 SELP ITGA2B
16 positive regulation of positive chemotaxis GO:0050927 9.56 F7 F3
17 regulation of blood coagulation GO:0030193 9.55 SERPINC1 GP1BA
18 plasminogen activation GO:0031639 9.54 PLAT FGA
19 negative regulation of fibrinolysis GO:0051918 9.52 SERPINE1 PLG
20 smooth muscle cell migration GO:0014909 9.51 PLAT ITGB3
21 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.49 PLG PLAT
22 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.48 F7 F3
23 blood coagulation, extrinsic pathway GO:0007598 9.46 F7 F3
24 negative regulation of synaptic transmission, dopaminergic GO:0032227 9.43 SLC6A4 PTGS2
25 blood coagulation GO:0007596 9.36 VWF SERPINC1 PLG PLAT P2RY12 ITGB3

Molecular functions related to Coronary Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 WDTC1 VWF SLC6A4 SERPINF1 SERPINE1 SERPINC1
2 signaling receptor binding GO:0005102 9.65 SERPINE1 PLG PLAT FGA F7
3 serine-type endopeptidase inhibitor activity GO:0004867 9.54 SERPINF1 SERPINE1 SERPINC1
4 serine-type endopeptidase activity GO:0004252 9.46 PLG PLAT F7 F3
5 fibrinogen binding GO:0070051 9.32 ITGB3 ITGA2B
6 protease binding GO:0002020 9.02 VWF SERPINE1 SERPINC1 ITGB3 F3

Sources for Coronary Thrombosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....